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Merkel Cell Carcinoma Dependence on Bcl-2 Family
Members for Survival
Monique E. Verhaegen1, Doris Mangelberger1, Jack W. Weick1, Tracy D. Vozheiko1, Paul W. Harms1,2,3,
Kevin T. Nash1, Elsa Quintana4,8, Paul Baciu1, Timothy M. Johnson1,5,6, Christopher K. Bichakjian1 and
Andrzej A. Dlugosz1,7
Merkel cell carcinoma (MCC), a rare but aggressive cutaneous neoplasm with high metastatic potential, has a
poor prognosis at late stages of disease with no proven chemotherapeutic regimens. Using an enriched culture
medium, we established and characterized 11 MCC cell lines for Bcl-2 family profiling and functional studies.
Immunoblot analysis revealed collectively high protein levels of prosurvival Bcl-2 members in cell lines and a
panel of MCC tumors. Downregulation of individual Bcl-2 proteins by RNAi promoted death in a subset of MCC
cell lines, whereas simultaneous inhibition of multiple family members by using the small-molecule antagonist
ABT-263 led to a marked induction of cell death in 10 of 11 lines. ABT-263 induced Bax-dependent apoptosis with
rapid cleavage of caspase-3 and PARP, regardless of Bcl-2 family profile or the presence of Merkel cell
polyomavirus. Furthermore, ABT-263 treatment led to rapid and sustained growth suppression of MCC xenografts
from a representative cell line, accompanied by a striking increase in apoptosis. Our results establish that
concurrent inhibition of multiple prosurvival Bcl-2 proteins leads to effective induction of apoptosis, and strongly
support the concept that targeting MCC dependence on these molecules may be useful therapeutically by
reversing an intrinsic resistance to cell death.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare but highly aggressive
neuroendocrine tumor of the skin, with a propensity for local,
regional, and distant metastasis. The primary lesion typically
presents in an elderly often immunosuppressed population,
on UV-exposed skin as an asymptomatic, although rapidly
expanding, tumor (Bichakjian et al., 2007; Schwartz et al.,
2013). Surgical excision is currently the mainstay of therapy
for primary lesions, plus lymph node dissection as needed,
and often in combination with radiation therapy (reviewed in
(Schrama and Becker, 2011)). Although MCC exhibits some
sensitivity to chemotherapeutic agents, clinical responses
are consistently short-lasting and recurrences are frequent.
To date, there is no widely accepted treatment strategy for
advanced disease (reviewed in (Desch and Kunstfeld, 2013;
Miller et al., 2013)), which invariably carries a poor prognosis.
The 5-year survival rate of 0–18% in patients presenting with
distant metastases highlights the urgent need for improved
therapeutic strategies (Allen et al., 2005).
Mounting evidence suggests that Merkel cell polyomavirus
(MCPyV) initially detected in 80% of MCC tumors is a key
player in MCC pathogenesis (reviewed in (Arora et al., 2012a).
Similar to other polyomaviruses, MCPyV harbors a T antigen
(TAg) oncoprotein locus encoding both large (L) and small (s)
TAgs, which are predicted to modulate both tumor suppressor
and cell cycle regulatory proteins. Although the requirement
of viral TAgs in MCPyV-positive MCC cells has been
demonstrated (Houben et al., 2010), their exact roles in cell
survival are not yet clearly defined. However, key mediators
of the intrinsic apoptotic pathway, prosurvival Bcl-2 and
Mcl-1, have been shown to be highly expressed in up to
85% (Kennedy et al., 1996; Feinmesser et al., 1999; Sahi
et al., 2012) and 88% (Brunner et al., 2008) of MCCs,
respectively.
Elevation of the prosurvival Bcl-2 family members (Bcl-2,
Bcl-xL, Mcl-1, Bcl-w, and A1) imparts survival advantages to
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tumor cells by providing an increased apoptotic threshold
(reviewed in (Juin et al., 2013)). This offers protection from
intrinsic proapoptotic tumor-suppressing pathways and onco-
genic signaling that would otherwise promote cell death,
suggesting that tumor cells exist in a ‘‘primed for death’’
state (Certo et al., 2006) and that removal of apoptotic
blockades may be sufficient to induce tumor cell death.
Hence, Bcl-2 was considered an attractive therapeutic target
in MCC (Schlagbauer-Wadl et al., 2000), but genetic targeting
proved to be ineffective in a Phase II trial in patients with
advanced MCC (Shah et al., 2009). This may not be surprising,
as evidence suggests that efficient apoptosis of cancer cells
may require simultaneous neutralization of multiple Bcl-2
proteins (Chen et al., 2005), driving the development of
targeted Bcl-2 family antagonists such as the orally bioavai-
lable ABT-263 (navitoclax) (Park et al., 2008; Tse et al., 2008).
This agent binds and inhibits Bcl-2, Bcl-xL, and Bcl-w and has
provided partial responses in Phase I trials in patients with
lymphoid malignancies (Roberts et al., 2012).
Here we demonstrate high expression levels of multiple
antiapoptotic Bcl-2 family members in human MCC tumors.
Further analysis of a panel of MCC cell lines that we generated
indicates high levels of both antiapoptotic and proapoptotic
family members, suggesting that blockade of apoptosis
through the collective activity of the antiapoptotic members
contributes to MCC tumor cell survival. In support of this
concept, we severely compromise MCC cell viability both
in vitro and in vivo by selectively targeting prosurvival Bcl-2
proteins. These preclinical data uncover the dependence of
the majority of human MCC cells on multiple antiapoptotic
Bcl-2 proteins for survival, and provide a strong rationale for
evaluating Bcl-2 family antagonists in the treatment of MCC.
RESULTS
Prevalence of Bcl-2 family members in MCC cells
The antiapoptotic Bcl-2 family members, often elevated in
cancer, regulate mitochondrial apoptosis via binding proa-
poptotic proteins (reviewed in (Bender and Martinou, 2013)).
To gain insight into the role of these proteins in MCC,
we focused our analyses on human MCCs, as well as 11
UM-MCC cell lines, that we have established (Materials and
Methods, Table 1, Supplementary Figures S1, S2, and Table S1
online). Immunoblotting using 16 human MCC lysates
(Figure 1a) indicates variable but high levels of Bcl-2 protein
in 94% of tumors, with Bcl-xL and Mcl-1 expressed to some
degree in all tumors, demonstrating the concurrent expression
of multiple prosurvival proteins in MCCs. The UM-MCC cell
line panel that we generated reveals expression of Bcl-2,
Bcl-xL, Mcl-1, and Bcl-w to some extent in all lines
(Figure 1b), with some variability and some expressing
markedly higher protein. As cell fate is ultimately regulated
by a balance of protein–protein interactions between proa-
poptotic and antiapoptotic Bcl-2 members, we also assessed
the levels of the multidomain (Bax, Bak) and multiple
BH3-only (Bim, Puma, Bad, Noxa, Bmf, and Bik) proapoptotic
family members (Figure 1b), and found that several of these
proteins are highly expressed in MCC cell lines. These data
reveal that, in addition to antiapoptotic proteins, MCC cells
also express multiple BH3-only prodeath proteins that may
require suppression to maintain cell survival.
Table 1. UM-MCC cell lines and patient demographics
MCC tumor Cell line
Patient no. Tumor type Site Age Gender Disease stage Designation Source Growth in vivo
1 Primary Scalp 92 M 1B UM-MCC9 Human Y
2 Metastasis Leg 54 F 3B UM-MCC13 Human ND
3 Primary Arm 54 M 3B UM-MCC623 NSG mice Y
3 Metastasis Axillary LN 54 M 3B UM-MCC624 NSG mice Y
4 Metastasis Inguinal LN 56 M 3B UM-MCC29 Human Y
5 Metastasis Axillary LN 85 M 3B UM-MCC31 Human Y
6 Primary Scalp 72 F 3B UM-MCC32 Human ND
6 Metastasis Postauricular LN 73 F 3B UM-MCC35 Human Y
7 Metastasis Axillary LN 88 M 3B UM-MCC34 Human Y
8 Metastasis Inguinal LN 79 F 3B UM-MCC40 Human Y
9 Primary Eyelid 71 F 1B UM-MCC565 NSG mice Y
10 Metastasis Axillary LN 79 F 3B UM-MCC19a Human ND
11 Metastasis Leg 62 M 3B UM-MCC49a Human ND
Abbreviations: LN, lymph node; MCC, Merkel cell carcinoma; ND, not determined.
Listed are MCC tumor type, site, age, gender, and disease stage at the time of tissue acquisition. Corresponding cell line designation is shown for each patient
tumor. Source of each UM-MCC cell line indicates direct establishment from patient tumors (human) or from human tumor xenografts in NOD/SCID/IL2Rgnull
(NSG) mice. Yes (Y) indicates tumorigenicity of MCC lines in athymic nude mice.
aIndicates cell lines lost to contamination.
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Role of antiapoptotic Bcl-2 family members in MCC cell survival
To assess their roles in MCC cell survival, Bcl-2, Bcl-xL, and
Mcl-1 were downregulated by using lentivirus-driven shRNA
constructs in several MCC cell lines. Individual protein knock-
down in UM-MCC565 led to marked decreases in cell number,
with 7%, 47%, and 32% of cells remaining following down-
regulation of Bcl-2, Bcl-xL, and Mcl-1, respectively. Micropho-
tographs and corresponding immunoblots indicate almost
complete downregulation of Bcl-2 and Mcl-1, and to a lesser
extent Bcl-xL (Figure 2a–c). Interestingly, the effect of individual
Bcl-2 protein knockdown was not consistent, and downregula-
tion in four additional lines, UM-MCC29 (Supplementary
Figure S4 online), -MCC40, -MCC32, and -MCC35 (data not
shown), had little effect. Exceptionally high levels of multiple
BH3-only prodeath proteins in UM-MCC565 (Figure 1b) may
provide one explanation for the sensitivity of these cells to
genetic targeting of single Bcl-2 antiapoptotic family members.
Targeting of multiple Bcl-2 family members induces MCC cell
death
To test the concept that Bcl-2 family members collectively
contribute to MCC cell survival, we used ABT-263, which is a
small-molecule Bcl-2 family inhibitor that simultaneously binds
Bcl-2, Bcl-xL, and Bcl-w, disrupting interactions with prodeath
proteins (Tse et al., 2008). Effects of ABT-263 treatment on cell
proliferation and viability of MCC cell lines are analyzed in
Figure 2d and e. With the exception of UM-MCC31, all lines
show decreases in cell number at concentrations as low as
0.5mM, in contrast to control skin cells, which were minimally
impacted. Furthermore, these lines demonstrate substantial cell
death comparable to, or higher than, the sensitive promyelo-
cytic leukemia cell line HL60, with 10 of 11 lines displaying
46–98% cell death at 24 hours (Figure 2e). Note that UM-
MCC31 is poorly responsive to ABT-263, more closely resem-
bling the SK-147 melanoma cell line that requires Mcl-1, which
is not targeted by ABT-263, for survival (Wolter et al., 2007).
Interestingly, the uniquely insensitive UM-MCC31 line displays
minimal BH3-only prodeath proteins (Figure 1b) and remains
insensitive even at late time points (not shown).
Apoptotic response of MCC cells to the Bcl-2 family antagonist
ABT-263
To begin unraveling the cytotoxic response of ABT-263, a
more detailed analysis was performed in four select lines
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Figure 1. Expression patterns of Bcl-2 family members in Merkel cell carcinoma (MCC) tumors and cell lines. (a) Immunoblotting depicts levels of Bcl-2, Bcl-xL,
and Mcl-1 in a panel of MCC tumors and normal skin. (b) Basal levels of antiapoptotic (Bcl-2, Bcl-xL, Mcl-1, Bcl-w), multidomain (Bax, Bak), and BH3-only (Bim,
Puma, Noxa, Bad, Bmf, Bik) Bcl-2 family members in UM-MCC cell lines. See Table 1 for patient tumor numbers and corresponding cell lines. Skin and skin cells:
foreskin (F) fibroblasts (F), keratinocytes (FK), and melanocytes (FM) are shown to indicate that normal tissue also expresses select antiapoptotic members
presumably needed for tight regulation of apoptosis. Melanoma cell lines (SK-Mel-19, -103) known to express high levels of prosurvival Bcl-2 members are shown
as positive controls (Verhaegen et al., 2006).
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(UM-MCC29; -MCC40; -MCC565; -MCC624). Typical MCC
aggregates are replaced by what appear to be single cells and
debris following ABT-263 treatment (Figure 3a). Time-course
studies indicate greater than 85% induction of cell death in all
four lines (Figure 3b). Further analysis of downstream signaling
reveals cleavage of apoptotic effectors caspase-3 and PARP as
early as 12 hours post treatment (Figure 3c).
To further evaluate MCC cell responsiveness to cytotoxic
agents, we compared the effects of ABT-263 and the DNA-
damaging agent carboplatin (Hospira, IL). We detectedp20%
cell death in three of five MCC lines following carboplatin
treatment (100mM), suggesting some level of apoptotic block-
ade. In contrast, with the exception of UM-MCC31, cells
largely unresponsive to carboplatin were highly sensitive to
ABT-263, with X81% cell death (Figure 4a). Responsive
HL60 cells are shown as a positive control for both cytotoxic
agents. Immunoblot analysis reveals that 5 of 11 cell
lines have detectable (stabilized) p53 (Figure 4b), which is
likely mutant or not fully functional, and as expected, these
lines are more resistant to carboplatin (Figure 4a) but not to
ABT-263.
We additionally screened the cell lines for expression levels
of apoptotic modulators downstream of the mitochondria,
including the inhibitor of apoptosis protein family members
survivin and XIAP (Figure 4b), known to block apoptosis at the
level of caspase activation. We found high levels of XIAP and
variable levels of survivin in all cell lines. Survivin has recently
been shown to be deregulated in most MCCs, although
regulation differs on the basis of MCPyV status (Xie et al.,
2014). Although UM-MCC cells with lower levels of survivin
(MCC13; MCC565) were slightly more sensitive to ABT-263
(Figure 2e), all lines underwent efficient ABT-263-induced
death regardless of inhibitor of apoptosis protein levels.
ABT-263 induces cell death in MCC cells regardless of MCPyV
status
As some MCCs do not express MCPyV, we examined whether
MCPyV status altered responsiveness to ABT-triggered cell
death. We initially established five MCPyV-positive cell lines
from 11 patients (45%); however, two lines were lost owing to
contamination, and hence our current panel includes only
three MCPyV-positive lines (Table 1, Supplementary Table S1,
Figures S1 and S2 online, Figure 4b). Our initial prevalence
rate, although substantially lower than the worldwide average
of 74% (reviewed in (Arora et al., 2012a), is in keeping with
the 46% prevalence of MCPyV that we previously reported in
the University of Michigan MCC cohort (Harms et al., 2013).
As previously described (Fischer et al., 2010), we also found
no correlation between phenotypic characteristics of our MCC
cell lines and MCPyV status (Supplementary Figure S1, S2, and
Table S1 online). MCPyV-positive UM-MCC lines expressed
TAg transcripts at levels similar to those in MKL-1 (Rosen
et al., 1987) and MKL-2 (Van Gele et al., 2002) confirmed
MCPyV-positive MCC cell lines (Shuda et al., 2008; Houben
et al., 2010) (Supplementary Figure S2d online). Loss of cell
viability in nearly all UM-MCC cell lines examined
(Figure 2e), and a more detailed comparison of two positive
and two negative cell lines following ABT-263 treatment
(Figures 3 and 4), demonstrates a marked induction of apop-
tosis irrespective of MCPyV status.
ABT-263 induces cell death in MCC cells regardless of
nontargeted Mcl-1 levels
One of the potential caveats of ABT antagonists are their
inability to bind Mcl-1, which leads to a reduced apoptotic
response in lymphomas and small-cell lung cancers
(Konopleva et al., 2006; van Delft et al., 2006). Surprisingly,
MCC cell lines with elevated Mcl-1 levels (Figure 1b) were
responsive to ABT-263. Assessment of Bcl-2 family members
during the course of treatment reveals that Mcl-1 levels
decrease markedly in three of the four lines studied, whereas
levels of antiapoptotic Bcl-2, Bcl-xL, and Bcl-w, as well as
proapoptotic effectors Bax and Bak, remain relatively stable
(Figure 4c). In contrast to other family members, Mcl-1 turns
over rapidly via ubiquitination and proteasomal degradation
(Zhong et al., 2005), and it can undergo caspase cleavage
(Herrant et al., 2004), which may explain the Mcl-1 loss.
Although the responsive UM-MCC624 maintains stable Mcl-1
levels during treatment (Figure 4c), it may be that the presence
of high Bak levels confers sensitivity to ABT by sequestering
Mcl-1, as has previously been shown (Konopleva et al., 2006).
Requirement for proapoptotic Bax in ABT-263-induced MCC cell
death
On the basis of what is known of its mechanism of action,
ABT-263 should activate the proapoptotic executioners Bax
and Bak at the mitochondria, leading to outer membrane
permeabilization, release of apoptogenic factors, and activa-
tion of downstream caspases and proteases (reviewed in
(Bender and Martinou, 2013)). To define their role in ABT-
263-driven apoptosis in MCC cells, Bax or Bak levels were
downregulated by using lentivirus-driven shRNA. Bax down-
regulation reduced cell death by B80% (24 hours) and
98% (48 hours) in UM-MCC29, whereas Bak downregulation
had little effect (Figure 5a–c). Furthermore, effects of
Bax shRNA reduced the killing activity of ABT-263 by 79,
82, and 94% in UM-MCC32, -MCC35, and -MCC565 cells,
respectively (Figure 5d).
ABT-263 induces apoptosis and blocks the growth of MCC
xenografts
Of the 9 UM-MCC cell lines tested, all generate tumors in
xenografts (Table 1), with histology closely resembling the
human MCCs from which they were derived (Supplementary
Figure S3 online; data not shown). UM-MCC29 was used to
test the response to ABT-263 in vivo. Growth kinetics of
tumors in control versus ABT-263-treated mice shows a
marked and sustained halt in growth (Figure 6a). A separate
experiment confirmed these results. H&E histology revealed
the typical small blue-cell morphology characteristic of MCC
in both control and treated tumors (Figure 6b), but the latter
were distinguished by the frequent presence of apoptotic
bodies (arrowheads). This was corroborated by a markedly
increased number of cells immunostaining for cleaved cas-
pase-3 and exhibiting a punctuate distribution of Bax indica-
tive of mitochondrial translocation (Figure 6c). On the basis of
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cleaved caspase-3 quantification, the frequency of apoptotic
cells was increased and maintained by B10-fold (Figure 6d
bottom). In contrast, staining for Ki67 and phosphorylated
histone H3 (Figure 6c) was quantitatively similar in tumors
from control versus treated mice at early and late time points
(Figure 6d top).
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Figure 2. Targeting antiapoptotic Bcl-2 proteins decreases Merkel cell carcinoma (MCC) cell viability. (a) Effects of individual Bcl-2 family knockdown in
UM-MCC565 via green fluorescent protein–expressing lentivirus-driven small hairpin RNA (shRNA) shown by brightfield and fluorescent microphotographs (day
4). Scale bars¼ 50mm. (b–c) Downregulation of targeted proteins is shown by immunoblotting, and quantitative analysis of viable cells is determined by Trypan
blue exclusion assay. A scrambled shRNA construct was used as a control (shCon). (d–e) Effects of ABT-263 on proliferation as determined by XTT assay (48 hours)
(d) or cell viability as determined by Trypan blue exclusion assay (24 hours) (e) in UM-MCC cell lines and control skin cells (FF, fibroblasts; FM, melanocytes;
FK, keratinocytes) or tumor cell lines (SK-Mel-147; HL60). Cells were treated with ABT-263 or dimethyl sulfoxide vehicle in complete medium.
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DISCUSSION
In this study, we identified and targeted antiapoptotic Bcl-2
proteins in MCC tumor cells in an effort to better understand
survival mechanisms that may be exploited for improved
treatment of this deadly malignancy. Classical DNA-damaging
agents are largely ineffective in MCC with short-lasting
responses, and are associated with high morbidity in elderly
patients (Voog et al., 1999). This has encouraged the deve-
lopment of mechanism-based targeted therapy. However, the
discovery of novel strategies to improve prognosis has
remained challenging, with progress in the field impaired
partly by the relative paucity of validated tumorigenic MCC
cell lines. We have established and characterized a panel of
11 MCC cell lines for functional studies using an enriched
growth medium.
Although overexpression of antiapoptotic Bcl-2 proteins has
been implicated in tumor pathogenesis, it is not necessarily a
predictor of tumor cell addiction (reviewed in (Juin et al.,
2013)). We therefore used genetic and pharmacological
targeting of the antiapoptotic proteins to functionally define
their role in MCC cell survival and ascertain the feasibility of
Bcl-2 family targeting as a treatment rationale. Our data
indicate that cell death in nearly all MCC lines could be
triggered by simultaneously targeting multiple Bcl-2 survival
proteins with the antagonist ABT-263, whereas genetic
inactivation of individual antiapoptotic Bcl-2 proteins results
in decreased cell viability in a subset of MCC cell lines. Our
findings may help explain why individual genetic targeting of
Bcl-2 was ineffective in MCC patients (Shah et al., 2009). The
frequent expression of multiple prosurvival proteins in MCC
implies that their collective activity, rather than any one
particular Bcl-2 family member, provides an increased apop-
totic threshold, which therefore requires broader targeting, as
can be achieved with ABT-263.
Although the exact binding hierarchy of antiapoptotic and
proapoptotic proteins remains somewhat controversial, inter-
actions resulting in Bax/Bak activation at the mitochondria
lead to activation of the apoptotic signaling cascade (reviewed
in (Bender and Martinou, 2013)). In keeping with this concept,
we find that genetic inactivation of Bax almost completely
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Figure 3. ABT-263 is a potent inducer of apoptosis in Merkel cell carcinoma (MCC) cells. (a) Microphotographs of representative MCPyV-positive or -negative
UM-MCC cell lines following treatment with ABT-263 (5mM) for 24 hours. Scale bars¼ 50mm. (b) Quantitative analysis of cell death by Trypan blue exclusion
assay over the indicated time course at 2mM (gray) and 5mM (black) concentrations. Similar responses at 2mM and 5mM are most likely due to Bcl-2-binding
saturation (Vogler et al., 2009). Cells were seeded, treated, and analyzed in triplicate. Vehicle control–treated cells are indicated as ‘nontreated’ (NT). Error bars
indicate SEM. (c) ABT-263 (5mM) induces apoptosis, as depicted by immunoblotting for cleaved (c) Caspase-3 (cCasp3) and cPARP as early as 12 hours post
treatment.
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abrogates ABT-induced MCC apoptosis in both MCPyV-
positive and -negative lines (Figure 5c, and d). In addition,
the widespread sensitivity of MCC cells to ABT-263 compared
with carboplatin indicates that targeting strategies at the level
of the mitochondria may be more effective than those acting
upstream, which likely rely on functional p53 signaling.
Moreover, ABT-induced cell death in MCC cells with high
levels of inhibitor of apoptosis protein family members
indicates that this agent can also efficiently bypass defects
downstream of the mitochondria as well.
With the discovery of MCPyV, the notion of targeting viral
proteins or associated pathways has become an attractive
MCC treatment option. For instance, the survivin-targeted
imidazole small-molecule inhibitor YM-155 was shown to
promote irreversible, nonapoptotic MCPyV-positive MCC cell
death (Arora et al., 2012b). However, here we demonstrate
that the Bcl-2 antagonist, ABT-263, induces widespread
apoptotic cell death as a single agent in MCC cells
regardless of MCPyV status. Furthermore, this apoptotic
response was accompanied by suppression of tumor growth
in vivo. Complete regression was not observed most likely
owing to unimpaired proliferation of tumors in treated mice
(Figure 6), suggesting that combined therapy with ABT-263
and a cytostatic agent may be a more effective approach to
treatment.
Our results, using a recently developed and characterized
panel of cell lines, establish that nearly all MCCs require the
collective activity of the antiapoptotic Bcl-2 family members
to restrain intrinsic prodeath signals. The use of the Bcl-2
antagonist ABT-263 induces Bax-dependent apoptosis both
in vitro and in vivo, regardless of additional apoptotic
signaling defects, or MCPyV status. These data identify the
increased apoptotic threshold in MCCs as a potential point of
vulnerability, warranting further investigation into the use of
Bcl-2 family antagonists for the treatment of these aggressive
malignancies.
MATERIALS AND METHODS
See Supplementary Materials and Methods online for further experi-
mental details and antibodies.
Acquisition of human tumors
Human tissue samples were collected from patients who provided
written informed consent for the use of surplus tissue according to a
protocol approved by the University of Michigan Institutional Review
Board (IRB Study ID: HUM00050085) in adherence to Helsinki
Guidelines. Tissue was collected according to protocols outlined
and approved under the same IRB. MCC diagnosis was established by
a board-certified dermatopathologist. Patient demographics and other
relevant information are listed in Table 1. Fresh tumor or normal skin
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Figure 4. ABT-263 induces widespread apoptosis in Merkel cell carcinoma (MCC) cells regardless of additional defects in apoptotic pathways, Merkel cell
polyomavirus (MCPyV) status, or Bcl-2 profile. (a) UM-MCC cell lines respond variably to the classical DNA-damaging agent carboplatin (100mM) compared with
ABT-263 (5mM), with UM-MCC31 uniquely resistant. Cell death was assessed by Trypan blue exclusion assay at 48 hours. (b) Immunoblotting for basal
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assessed by Trypan blue exclusion assay is shown at each time point. Vehicle control–treated cells are indicated as ‘nontreated’ (NT).
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tissue was collected in cold Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technologies, Frederick, MD) supplemented with
500 U ml 1 penicillin/streptomycin until further processing.
Establishment of MCC cell lines and tissue culture
MCC cell lines were established from tumor tissue procured as
described above. Cell lines UM-MCC9, 13, 29, 31, 32, 34, 35, and
40 were derived directly from solid patient tumors; UM-MCC565,
623, and 624 were established from tumors arising in NOD /SCID/
IL2Rgnull (NSG) mice (The Jackson Laboratory, Bar Harbor, ME),
following injection of human MCC cells in a xenotransplantation
model, as previously described (Quintana et al., 2008)
(Supplementary Figure S1 online; Table 1). All cell lines were
established in a modified neural crest stem cell self-renewal medium
(Molofsky et al., 2005) supplemented with 15% chick embryo extract
(Stemple and Anderson, 1992). Melanocytes, keratinocytes, and
fibroblasts, as well as melanoma cell lines, were isolated and
cultured as previously described (Verhaegen et al., 2006). HL60,
MKL-1, and MKL-2 cell lines were maintained in RPMI supplemented
with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA).
Reagents
ABT-263 (Accela ChemBio, San Diego, CA) was diluted as needed in
culture medium or resuspended daily by sonication in 60% Phosal 50
PG (Phospholipid, Koeln, Germany), 30% polyethylene glycol (PEG)
400 (Sigma-Aldrich, St Louis, MO), and 10% ethanol for in vivo
studies.
Analysis of cell proliferation and cell viability
Assessment of cell proliferation was performed using an XTT Cell
Proliferation Assay kit (ATCC, Manassas, VA), and cell death
was determined by standard Trypan blue exclusion assays. All
experiments were performed in triplicate and data are presented as
the mean±SEM.
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Figure 5. Induction of Merkel cell carcinoma (MCC) cell death by ABT-263 is Bax dependent. (a–c) Effects of Bax or Bak knockdown on apoptotic
response of ABT-263 treatment in UM-MCC29. Brightfield or fluorescent microphotographs (a) are shown with green fluorescent protein (shCon, shBax)
or red fluorescent protein (shBak) under control of the human ubiquitin-C promoter to monitor transduction efficiency. Scale bars¼ 50mm. Efficacy and
selectivity of downregulation are validated by immunoblotting (b). Quantitative analysis by Trypan blue exclusion assay following ABT-263 (5mM) treatment (c).
(d) Quantitative analysis of cell death by Trypan blue exclusion assay 24 h post treatment with ABT-263 (2mM) following Bax downregulation (insets show
Bax immunoblots) in cell lines UM-MCC32, -MCC35, and -MCC565. Error bars indicate SEM. NT indicates vehicle control–treated cells.
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Protein immunoblots
Total cell line lysates were obtained by Laemmli extraction, and human
tumor lysates were prepared by mechanical homogenization in RIPA
buffer supplemented with HALT phosphatase inhibitor cocktail (Thermo
Scientific, Vernon Hills, IL) and Complete mini protease inhibitor
cocktail (Roche, Indianapolis, IN). Protein was quantified by the
standard Bradford method using the Bio-Rad Protein Assay dye reagent
(Bio-Rad Laboratories, Hercules, CA) and separated on 4–20% gradient
SDS-polyacrylamide gels and transferred to Immobilon-P membranes
(Millipore, Billerica, MA). Detection was carried out with SuperSignal
West Pico or Femto chemiluminescent substrates (Thermo Scientific).
Genetic inactivation: RNA interference
Downregulation of apoptotic mediators Bcl-2, Bcl-xL, Mcl-1, Bax,
and Bak was accomplished using lentivirus-driven shRNA constructs,
as previously reported (Verhaegen et al., 2006). Lentiviruses were
generated in 293FT cells, and viral titers were collected for infection
of MCC cell lines.
Treatment of UM-MCC cell lines as tumor xenografts
Athymic nude-Foxn1nu mice (Harlan Laboratories, Indianapolis, IN)
were kept in specific pathogen-free conditions and used at 5–6 weeks
of age in procedures approved by the University Committee on the
Use and Care of Animals (animal protocol #PRO00004440). ABT-263
effectiveness in vivo was analyzed by oral daily dosing at 100 mg/kg
for 18 days (d18) when UM-MCC29 xenografts reached a volume of
250–300 mm3. Control mice were dosed with resuspension diluent
(n¼ 12 tumors per condition). Mice were killed 8 days post treatment
(d8) or upon treatment termination (d18).
Immunohistochemical staining
Human or mouse xenograft tumors were fixed in 10% neutral-
buffered formalin followed by routine paraffin embedding and
processing for immunohistochemical staining (including deparaffini-
zation, rehydration, and antigen retrieval in boiling 0.01 M
citric acid solution, pH 6.8). Vector M.O.M. fluorescein or
peroxidase Immunodetection Kits (Vector Laboratories, Burlingame,
CA) were used for detection with SigmaFast diaminobenzidene
as a peroxidase substrate. Nuclei were counterstained with
hematoxylin.
Statistics
Statistical analysis of tumor growth in vivo after ABT-263 treatments
was performed using an unpaired two-tailed Student’s t-test.
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Figure 6. ABT-263 inhibits Merkel cell carcinoma (MCC) tumor growth and induces apoptosis in vivo. (a) Tumor volume (V¼ LW2/2; L¼ length, W¼width) of
UM-MCC29 xenografts in control or ABT-263-treated mice. Photo depicts mice 18 days post ABT-263 (d18). Error bars indicate SEM (n¼ 12). *Po0.05 or
**Po0.005, respectively. (b) H&E staining at d8 and d18. Arrowheads indicate apoptotic cells. (c) Immunostaining for proliferation markers Ki67 and pH H3 as
well as apoptotic markers cCasp3 and Bax translocation (d18). (d) Quantitative analysis of pHisH3 and cCasp3 cell counts at d8 (bars indicate range for n¼ 2) and
d18 (bars indicate SEM for n¼4). Approximately 1,500 cells from randomly selected fields were counted for each tumor analyzed. Scale bars¼25mm.
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